Retatrutide vs Tirzepatide vs Semaglutide vs Ozempic

This is the page for the person mid-decision. You took semaglutide, lost weight, stalled. You moved to tirzepatide, lost more, stalled again. Now you read about the drug people call "Godzilla" and wonder if its third hormone moves the scale once more. Below is the plain comparison, the real trial numbers with their sources, the one honest catch nobody online tells you, and the safe way to switch.

One thing said plainly. Retatrutide is investigational and not FDA-approved for any use. Compounded retatrutide is not FDA-approved either, and the FDA does not review it for safety, effectiveness, or quality. Semaglutide and tirzepatide are FDA-approved for weight management under their brand names. Every trial number on this page names its trial. None of it promises your result. A licensed provider decides whether any treatment fits you.

What is the difference between retatrutide, tirzepatide, and semaglutide?

The difference is how many hormones each drug works on. Semaglutide works on one, tirzepatide on two, and retatrutide on three. Each added hormone is another lever on appetite and metabolism, and in the trials, more levers meant more weight loss. All three are once-weekly shots.

Here is each one in plain words. A hormone is a chemical messenger your body uses to control hunger and how it handles food.

Semaglutide works on one hormone, GLP-1. GLP-1 (glucagon-like peptide-1) quiets appetite and steadies blood sugar. It is the hormone behind that "I forgot to eat" feeling. Semaglutide is sold as Ozempic for diabetes and Wegovy for weight loss. Same drug, two brand names.

Tirzepatide works on two hormones, GIP and GLP-1. GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone that helps with insulin and blood sugar. Adding it is why tirzepatide outperformed semaglutide in a head-to-head trial, covered below. Tirzepatide is sold as Mounjaro and Zepbound.

Retatrutide works on three hormones. It keeps GIP and GLP-1 and adds a third, glucagon. Glucagon is the new piece. When you diet, your body burns fewer calories to protect itself. Glucagon pushes the other way, toward burning more energy and more fat (Lilly Medical).6 That third hormone is why people nickname the drug "Godzilla," and why some say it gave their energy back instead of leaving them flat. The retatrutide overview digs into how that third hormone works.

The ladder is one hormone, two, then three. The trial numbers climb the same way.

Retatrutide vs tirzepatide vs semaglutide: the trial weight-loss numbers

In their own trials, semaglutide reached about 15% mean weight loss, tirzepatide about 21%, and retatrutide up to 24% at 48 weeks, with a phase 3 topline of up to 28.7%. The numbers climb with the number of hormones. The catch: these come from separate trials, not one head-to-head study, so treat them as a guide, not a photo finish.

Here is how the three compare. Semaglutide (Ozempic, Wegovy) targets one hormone, GLP-1, is a weekly shot, reached about 15% in STEP 1 at the 2.4 mg dose over 68 weeks (Wilding et al., NEJM 2021), and is FDA-approved. Tirzepatide (Mounjaro, Zepbound) targets two hormones, GIP and GLP-1, is a weekly shot, reached about 21% in SURMOUNT-1 at the 15 mg dose over 72 weeks (Jastreboff et al., NEJM 2022), and is FDA-approved. Retatrutide (investigational, no brand) targets three hormones, GIP, GLP-1, and glucagon, is a weekly shot, reached up to 24.2% in phase 2 at the 12 mg dose over 48 weeks (Jastreboff et al., NEJM 2023), with a phase 3 topline up to 28.7% at 68 weeks (TRIUMPH-4), and is not FDA-approved. These figures come from separate trials with different people, doses, and lengths, so they are a rough guide, not a fair apples-to-apples comparison.

Whether you searched tirzepatide vs retatrutide or retatrutide vs tirzepatide, the order does not change the answer. Here is what each number means and where it comes from.

Semaglutide reached about 15% mean weight loss in the STEP 1 trial at 68 weeks on the 2.4 mg dose (Wilding et al., NEJM 2021).3 That is the obesity dose, sold as Wegovy.

Tirzepatide reached about 21% mean weight loss in the SURMOUNT-1 trial at 72 weeks on the 15 mg dose (Jastreboff et al., NEJM 2022).2 The second hormone shows up as a bigger number.

Retatrutide reached up to 24.2% mean weight loss at 48 weeks on the 12 mg dose in its phase 2 trial (Jastreboff et al., NEJM 2023).1 In December 2025, Lilly reported a phase 3 topline from TRIUMPH-4: up to 28.7% at 68 weeks, an average of more than 70 pounds. That 28.7% is a topline figure, with full peer-reviewed data still pending (HCPLive; PharmExec).9 Worth noting, in that 48-week phase 2 trial people were still losing weight when it ended (Eli Lilly).7

Now the honest catch, said once and plainly. No trial has put reta head-to-head against tirz or sema. The figures above come from different trials, with different people, different lengths, and different rules. Lining them up looks like a clean race, but it is not one. The order is probably right. The exact gap is not something cross-trial numbers can prove. We would rather tell you that than sell you a false certainty.

(A quick note on shorthand. People online call retatrutide "reta," tirzepatide "tirz," and semaglutide "sema." We use those short names in places below.)

Have tirzepatide and semaglutide ever been compared directly?

Yes. Tirzepatide and semaglutide were tested head-to-head in one trial, SURMOUNT-5. Tirzepatide won. At 72 weeks, people on tirz lost about 20% of their body weight and people on sema lost about 14% (NEJM 2025).4 Reta was not in that trial, so its number stays a cross-trial estimate.

This matters for your decision. The one place we have a real side-by-side, the drug with more hormones came out ahead. That is the pattern the trial numbers suggest, and the SURMOUNT-5 result is the cleanest evidence for it (Applied Clinical Trials).5 It is also a fair warning. Until retatrutide gets its own head-to-head trial, the "triple beats dual" story is a strong hunch supported by separate trials, not a proven finish.

So when you see reta's bigger percentage, hold it the right way. The direction is believable. The exact margin is not settled.

Should I switch from tirzepatide or semaglutide to retatrutide?

Maybe. If your current drug still works and you feel good, you may have no reason to change. People say it themselves: if it ain't broke, don't fix it. The case to switch is real when the scale has stalled for months, or when the old drug drained your energy or cost you muscle. A provider helps you tell a true plateau from a bad few weeks.

Here is the pattern we hear most. Someone loses on sema, stalls after a while, moves to tirz, loses more, then stalls again. Now they want to know if reta's third hormone can move the scale one more time. Often it can, in the trials. But "switch" is the wrong word for what actually happens. You are not swapping one pill for another. You are starting a new drug at a new dose and raising it slowly.

That is where people get hurt going it alone. The doses do not carry over one-to-one. Someone on 15 mg of tirz cannot read across to a matching reta dose, because no conversion chart exists. Guess too low and you feel nothing. Guess too high and, in one person's words, you end up "mega sick." A provider sets your starting dose, watches how you respond, and raises it on a safe schedule. The retatrutide dosing schedule lays out that provider-paced ramp.

Will retatrutide give me energy that tirzepatide and semaglutide took away?

Some people say yes, and the reason is the third hormone. On sema and tirz, plenty of people feel flat and drained as the weight comes off. On reta, some feel the opposite. The likely reason is glucagon, which nudges the body toward burning energy instead of storing it. The honest part: it does not happen for everyone.

This is the most repeated hope among switchers, and the words are striking. "I switched from Tirz to Reta because of fatigue, and my energy level with Reta is far better," one person wrote. Another, weighing the trade-off: "I'd take mild physical discomfort over anhedonia and lethargy any day." When you cut calories, your body slows down to protect itself, and that slowdown is part of why diets leave people feeling tired and dull. Glucagon works against it (Lilly Medical).6

Now the other side, because it is the reason supervision wins. Some people feel more tired or run cold early, especially right after a dose jump. The same glucagon can also nudge your resting heart rate up. None of that is a reason to panic. A provider handles it with a slower dose climb, shot timing, and electrolytes, and watches your heart rate while it settles. The energy numbers people quote online come from glucagon research, not from the reta weight-loss trial, which did not measure energy use, so no one can promise you a boost.

Which drug keeps the most muscle?

No trial has compared these drugs on muscle directly, so there is no clean answer. Fast weight loss of any kind costs some muscle along with fat. What people report is that the energy to keep training matters, and some say they trained more easily on reta than on tirz. That is lived experience, not trial data.

The fear is real and specific. "Tirz exhausted me badly, couldn't even strength train, so now I lost all my muscle and I'm saggy," one person wrote. Whether retatrutide protects muscle better is not something the trials answer. What helps muscle is steadier energy to keep lifting, enough protein, and a dose that climbs slowly instead of dropping weight too fast. Those are things a provider can build into your plan, and they apply on any of these drugs.

So treat the "reta keeps muscle" claim as hopeful and unproven. The thing that actually protects muscle is how you run the plan, not the drug alone.

Is retatrutide better than Ozempic and Wegovy?

In the trial numbers, retatrutide reached a higher mean weight loss than semaglutide, which is the drug in Ozempic and Wegovy. But "better" depends on more than the biggest percentage. Ozempic and Wegovy are FDA-approved and well studied. Reta is investigational and not approved. That trade is the real decision.

First, the name confusion, cleared up. Ozempic and Wegovy are both semaglutide. Same drug, different brand and dose: Ozempic is the diabetes brand, Wegovy is the weight-loss brand. So "retatrutide vs Ozempic" and "retatrutide vs Wegovy" are both really "retatrutide vs semaglutide."

On weight loss, the trials favor retatrutide: up to 24.2% at 48 weeks (Jastreboff et al., NEJM 2023) against about 15% for semaglutide (Wilding et al., NEJM 2021). On track record, sema wins. It has years of approved use and a long safety record. Reta is still in phase 3 trials, so its long-term safety data is not in yet.

That is why the choice belongs with a provider, not a forum. The strongest number is not automatically the right drug for your history, your heart, and your goals. A provider weighs all of it.

What is the safe way to switch, and where does Get Pep'd fit?

The safe way to switch is supervised. A provider licensed in your state reviews your history, sets your starting dose, and raises it on a schedule, while a licensed US pharmacy fills the prescription. The unsafe way is stacking forum advice and guessing your dose from a stranger's vial. The whole risk of switching lives in the dose and the source, and supervision removes both.

Because reta is still in trials, you cannot buy it off a shelf, and most of what people find online is gray-market that you cannot verify yourself, which the retatrutide overview covers in full. A provider and a pharmacy can verify it.

With Get Pep'd, the path starts with a short, free health check. A licensed provider reads your information, including your own bloodwork, and decides whether a weight-loss treatment is right for you. You only pay if a provider prescribes. Your dose is set and labeled for you, so there is no mixing and no math, and someone watches your numbers while the dose climbs. That is the difference between switching safely and gambling alone.

This content is for educational purposes and is not medical advice. Retatrutide is investigational and not FDA-approved for any use. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Trial figures cited here are average results from the named clinical trials, not a promise of individual results. A licensed provider determines whether any treatment is appropriate for you. Results vary.